PE20031018A1 - Compuestos oxo-azabiciclicos - Google Patents

Compuestos oxo-azabiciclicos

Info

Publication number
PE20031018A1
PE20031018A1 PE2003000218A PE2003000218A PE20031018A1 PE 20031018 A1 PE20031018 A1 PE 20031018A1 PE 2003000218 A PE2003000218 A PE 2003000218A PE 2003000218 A PE2003000218 A PE 2003000218A PE 20031018 A1 PE20031018 A1 PE 20031018A1
Authority
PE
Peru
Prior art keywords
alkyl
oxo
compounds
metoxy
benzylamide
Prior art date
Application number
PE2003000218A
Other languages
English (en)
Inventor
Bernard Gaudilliere
Henry Jacobelli
Wen-Song Yue
Jack Jie Li
Catherine Kostlan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20031018A1 publication Critical patent/PE20031018A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS OXO-AZABICICLICOS DE FORMULA I DONDE X1, X2, X3 SON N, -CR3 DONDE R3 REPRESENTA UN GRUPO SELECCIONADO DE H, ALQUILO C1-C6, AMINO, MONOALQUILAMINO C1-C6, DIALQUILAMINO C1-C6, HIDROXI, ALCOXI C1-C6, ENTRE OTROS CON LA CONDICION QUE NO MAS DE DOS DE LOS GRUPOS X1, X2 Y X3 SON N; G1 ES EL GRUPO a, b DONDE EL ATOMO DE CARBONO CON EL NUMERO 2 ESTA UNIDO AL GRUPO N-R1 DEL ANILLO; R4 Y R5 SON H, ALQUILO C1-C6, ARLO, ARILALQUILO C1-C6, CICLOALQUILO, CICLOALQUILALQUILO C1-C6, HETEROCICLOALQUILALQUILO C1-C6; R4 ES H, TRIFLUOROMETILO, OR7, NR7R8 DONDE R7 Y R8 SON H, ALQUILO C1-C6, ENTRE OTROS; G2 ES UN ENLACE TRIPLE CARBONO-CARBONO, -CH=C=CH-, -C=O, C=S, S(O)n1 DONDE n1 ES DE 0 A 2; n ES 0-6; Z1 ES -CR9R10 DONDE R9 Y R10 SON H, ALQUILO C1-C6, TRIHALOGENO ALQUILO C1-C6, ENTRE OTROS; A ES ARILO, HETEROARILO, ENTRE OTROS; R1 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 4-METOXI-BENCILAMIDA DEL ACIDO 3-(4-DIHIDRO-QUINAZOLIN-6-CARBOXILICO, CLORHIDRATO DE 4-METOXI-BENCILAMIDA DEL ACIDO 3-(4-METOXI-BENCIL)-2-METIL-4-OXO-3,4-DIHIDRO-QUINAZOLIN-6-CARBOXILICO, 4-METOXI-BENCILAMIDA DEL ACIDO 3-(4-METOXI-BENCIL)-1-METIL-4-OXO-1,2,3,4-TETRAHIDRO-QUINAZOLIN-6-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION Y UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES ESPECIFICOS DE LA METALOPROTEASA DE LA MATRIZ DE TIPO 13 UTILES EN EL TRATAMIENTO DE ARTRITIS, OSTEOARTRITIS
PE2003000218A 2002-03-08 2003-03-06 Compuestos oxo-azabiciclicos PE20031018A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/003240 WO2003076416A1 (en) 2002-03-08 2002-03-08 Oxo azabicyclic compounds

Publications (1)

Publication Number Publication Date
PE20031018A1 true PE20031018A1 (es) 2004-01-09

Family

ID=27798761

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000218A PE20031018A1 (es) 2002-03-08 2003-03-06 Compuestos oxo-azabiciclicos

Country Status (25)

Country Link
EP (1) EP1492775A2 (es)
JP (1) JP2005526070A (es)
KR (1) KR20040095270A (es)
CN (1) CN1738806A (es)
AP (1) AP2004003125A0 (es)
AR (1) AR039562A1 (es)
AU (2) AU2002249275A1 (es)
BR (1) BR0308280A (es)
CA (1) CA2478706A1 (es)
CO (1) CO5601020A2 (es)
EA (1) EA200401053A1 (es)
EC (1) ECSP045278A (es)
IL (1) IL163818A0 (es)
IS (1) IS7414A (es)
MA (1) MA27183A1 (es)
MX (1) MXPA04008681A (es)
NO (1) NO20044041L (es)
OA (1) OA12782A (es)
PA (1) PA8568501A1 (es)
PE (1) PE20031018A1 (es)
PL (1) PL372622A1 (es)
SV (1) SV2003001495A (es)
TN (1) TNSN04169A1 (es)
UY (1) UY27700A1 (es)
WO (2) WO2003076416A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
CA2495293A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
MXPA05001785A (es) 2002-08-13 2005-04-25 Warner Lambert Co Derivados de cromona como inhibidores de las metaloproteinasas de matriz.
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
EP1537098A1 (en) 2002-08-13 2005-06-08 Warner-Lambert Company LLC Monocyclic derivatives as matrix metalloproteinase inhibitors
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
JP2006500351A (ja) 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテアーゼ−13阻害剤としてのピリミジン−2,4−ジオン誘導体
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
DE10360835A1 (de) * 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
MXPA06012333A (es) * 2004-04-30 2007-01-17 Takeda Pharmaceutical Compuesto de amida heterociclico y uso del mismo como un inhibidor mmp-13.
CA2568756A1 (en) * 2004-06-15 2005-12-29 Astrazeneca Ab Substituted quinazolones as anti-cancer agents
WO2008043087A2 (en) 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
WO2012052451A1 (en) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators
CN103524431B (zh) * 2013-09-24 2016-01-13 西安交通大学 3-苄基-4-喹唑啉酮类化合物及其合成方法和应用
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
CA2996989C (en) 2015-09-23 2023-10-03 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
HUE050567T2 (hu) 2015-09-23 2020-12-28 Janssen Pharmaceutica Nv Triciklusos heterociklusok rák kezelésére
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9714222A (pt) * 1996-12-17 2000-04-18 Du Pont Método para o controle de doenças de plantas
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13

Also Published As

Publication number Publication date
OA12782A (en) 2006-07-10
AP2004003125A0 (en) 2004-09-30
CN1738806A (zh) 2006-02-22
EP1492775A2 (en) 2005-01-05
TNSN04169A1 (fr) 2007-03-12
MXPA04008681A (es) 2004-12-06
KR20040095270A (ko) 2004-11-12
CA2478706A1 (en) 2003-09-18
BR0308280A (pt) 2004-12-28
JP2005526070A (ja) 2005-09-02
ECSP045278A (es) 2004-10-26
MA27183A1 (fr) 2005-01-03
PA8568501A1 (es) 2003-12-19
NO20044041L (no) 2004-10-07
WO2003076417A3 (en) 2003-11-13
SV2003001495A (es) 2003-11-04
EA200401053A1 (ru) 2005-04-28
AU2003212307A1 (en) 2003-09-22
WO2003076416A1 (en) 2003-09-18
AR039562A1 (es) 2005-02-23
UY27700A1 (es) 2003-10-31
PL372622A1 (en) 2005-07-25
AU2002249275A1 (en) 2003-09-22
IS7414A (is) 2004-08-19
CO5601020A2 (es) 2006-01-31
WO2003076417A2 (en) 2003-09-18
IL163818A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
PE20031018A1 (es) Compuestos oxo-azabiciclicos
PE20181491A1 (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen
CR8266A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
UY28150A1 (es) Agentes terapeuticos
PE20030413A1 (es) Acido homoiminopiperidinilo hexanoico como inhibidores de oxido nitrico sintasa
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
DOP2003000566A (es) Cicloalcanindoles con sustitución con fluor, composiciones que contienen estos compuestos y metodos de preparación para un medicamento
BR0312999A (pt) Compostos, composições farmacêticas, método para aumentar a cognição, de tratamento, de inibição da atividade de enzima pde4 em um paciente
ES2094721T3 (es) Analogos de la camptotecina solubles en agua.
IS2503B (is) Ný efnasambönd
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
BRPI0201437B8 (pt) processos para a preparação de derivados de 9-desoxo-9a-aza-9a-homoeritromicina a 4"-substituídos
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
PE20010126A1 (es) Pirrolotriazinas como inhibidores de cinasas
PE20010112A1 (es) Compuestos no esteroides como moduladores del receptor glucocorticoide
BR122018007328B8 (pt) composto, composição farmaceutica e uso do dito composto
UY27437A1 (es) Compuestos químicos
UY28695A1 (es) Derivados de difenilazetidona
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
PE34297A1 (es) Ligandos especificos del neuropeptido y1
UY27503A1 (es) Nuevos derivados de piperazina
UY27786A1 (es) Derivados de isoquinolina.
UY27853A1 (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal